



15 September 2004

## **Animal Trials Commence Using VitroGro®**

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has progressed its efforts to develop a treatment for human burns based on its proprietary VitroGro® technology with the commencement of animal trials today.

The animal trials to assess the potential of VitroGro® as a human burns treatment are being conducted by leading Australian burns surgeons based at the Royal Children's Hospital in Brisbane.

Tissue Therapies Chairman Roger Clarke said the animal-based trials are aimed at developing VitroGro® products for more effective treatment of paediatric burns.

“The opportunity to expand the scope and rigour of the trials arose during the planning phase. We now expect the animal trials to continue for approximately 120 days, which includes a repeat of the trial to reconfirm the outcomes.”

“The trials are designed to seek new and valuable data and if successful, will support the possible design of human trials using VitroGro®.”

The animal trials are managed by leading paediatric burns surgeon, Associate Professor Roy Kimble, based at the Royal Children's Hospital in Brisbane.

Dr Kimble is Clinical Director of the Stuart Pegg Paediatric Burns Centre and Head of the Royal Children's Hospital Burns Research Group (a co-operative research team comprising staff of the Department of Paediatrics and Child Health, University of Queensland and the Royal Children's Hospital, Queensland Health).

### ***ENDS***

Further information:

Dr Zee Upton  
Chief Scientific Officer, Tissue Therapies Limited  
Mobile: 0404 816 844  
z.upton@tissuetherapies.com

Roger Clarke  
Chairman, Tissue Therapies Limited  
Telephone: 07 3334 4832

Dr Roy Kimble  
royk@uq.edu.au

## **About Tissue Therapies Limited**

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue and cell culture.

The Company has worldwide exclusive rights to commercialise VitroGro®, a platform technology developed by tissue engineering experts at Queensland University of Technology for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration and cell culture.

Based on its VitroGro® platform technology, Tissue Therapies is developing more effective medical treatments for wounds and burns, integration of orthopaedic and medical implants, and other applications such as the development of a platform for the culture of dendritic cells for cancer immunotherapy vaccines.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for research and industrial cell culture markets internationally.

Distributed by:            Libby Baynton  
                                  NOUS Corporate  
                                  Tel: 0414 517 784  
                                  libby@nous.com.au

**For more information: [www.tissuetherapies.com](http://www.tissuetherapies.com)**